Paesold Günther, Nerlich Andreas G, Boos Norbert
Centre for Spinal Surgery, University of Zürich, Balgrist, Zurich, Switzerland.
Eur Spine J. 2007 Apr;16(4):447-68. doi: 10.1007/s00586-006-0220-y. Epub 2006 Sep 16.
Recent advances in molecular biology, cell biology and material sciences have opened a new emerging field of techniques for the treatment of musculoskeletal disorders. These new treatment modalities aim for biological repair of the affected tissues by introducing cell-based tissue replacements, genetic modifications of resident cells or a combination thereof. So far, these techniques have been successfully applied to various tissues such as bone and cartilage. However, application of these treatment modalities to cure intervertebral disc degeneration is in its very early stages and mostly limited to experimental studies in vitro or in animal studies. We will discuss the potential and possible shortcomings of current approaches to biologically cure disc degeneration by gene therapy or tissue engineering. Despite the increasing number of studies examining the therapeutic potential of biological treatment strategies, a practicable solution to routinely cure disc degeneration might not be available in the near future. However, knowledge gained from these attempts might be applied in a foreseeable future to cure the low back pain that often accompanies disc degeneration and therefore be beneficial for the patient.
分子生物学、细胞生物学和材料科学的最新进展开启了一个用于治疗肌肉骨骼疾病的新兴技术领域。这些新的治疗方式旨在通过引入基于细胞的组织替代物、对驻留细胞进行基因改造或二者结合来对受影响组织进行生物修复。到目前为止,这些技术已成功应用于各种组织,如骨骼和软骨。然而,将这些治疗方式应用于治疗椎间盘退变尚处于非常早期的阶段,且大多局限于体外实验研究或动物研究。我们将讨论当前通过基因治疗或组织工程对椎间盘退变进行生物治疗方法的潜力和可能存在的不足。尽管研究生物治疗策略治疗潜力的研究数量不断增加,但在不久的将来可能仍无法获得常规治愈椎间盘退变的可行解决方案。然而,从这些尝试中获得的知识可能会在可预见的未来应用于治疗常伴随椎间盘退变的腰痛,从而使患者受益。